Evidence map›Paper›PMID 39976103›Full record

ReviewCurrent vascular pharmacology2026

Tumor-Associated Pericytes: Tumorigenicity and Targeting for Cancer Therapy.

Jiale Tan, Zihang Yu, Ruozheng Pi, Yan Lin, Wei Wang, Minfeng Chen, Xue Bai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current vascular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiale TanDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zihang YuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ruozheng PiDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yan LinDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wei WangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Minfeng ChenCollege of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
Xue BaiDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

Fundamental Research Funds for The Central Universities 21624103Guangdong Basic and Applied Basic Research Foundation 2024A1515011372, 2024B1515020098National Natural Science Foundation of China 82272731Science and Technology Projects in Guangzhou 2023A04J2372
6 · The paper itself

Abstract

Pericytes, also known as mural cells, are cells embedded between endothelial cells and the basement membrane of capillaries, where they orchestrate the morphological and functional homeostasis of blood vessels. Within the tumor microenvironment, pericytes interact closely with various cellular components, including tumor cells, stromal cells, and immune cells. Through these dynamic interactions, pericytes are activated and subsequently transform into tumor-associated pericytes (TPCs). The origin of TPCs varies depending on the tissue and tumor type, contributing to their phenotypic and functional heterogeneity. TPCs play pivotal roles in facilitating tumor progression, metastasis, immune evasion, and therapeutic resistance by promoting angiogenesis, engaging in reciprocal interactions with tumor cells, remodeling the extracellular matrix, and fostering an immunosuppressive microenvironment. This review synthesizes the latest significant advancements in targeted therapies against TPCs. It underscores the challenges inherent in developing effective anti-TPC therapies, which include the heterogeneity and pluripotency of TPCs, the absence of specific markers for precise TPC targeting, and the limited understanding of how current anti-tumor therapies affect TPCs and vice versa. This review furnishes a comprehensive understanding of the origins, markers, and functions of TPCs, and their interplays within the tumor microenvironment, providing prospective strategies for more effective anti-tumor therapy.

Indexed as

Antineoplastic AgentsNeoplasmsPericytesAnimalsHumansMolecular Targeted TherapyNeovascularization, PathologicSignal TransductionTumor MicroenvironmentAntineoplastic Agentsangiogenesiscancer therapyheterogeneityimmunomodulationTumor-associated pericytestumor microenvironment

Identifiers

PMID39976103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.